natgillin/translations-raw huggingface dataset:
Hvid, oval, med skrå kanter, delekærv på begge sider og præget med ”P7” på begge halvdele af den ene side af tabletten. 
White, oval, with bevelled edges, both sides scored, with imprint "P7" on both halves of one side of the tablet.
Tel: + 31 (0)75 612 05 11 
Focus Care Pharmaceuticals B.V. Tel: +31 (0)75 612 05 11
- Unormale, ufrivillige bevægelser (dyskinesi) - Øget muskelaktivitet med ufrivillige bevægelser (hyperkinesi)* - Paranoia (f.eks. overdreven frygt for ens eget helbred)* - Vrangforestillinger* - Hukommelsestab (amnesi)* - Hallucinationer (at se, høre eller føle ting, som ikke er der) - Forvirring - Udtalt træthed om dagen og episoder med pludselig indsættende søvn - Tager på i vægt - Lavt blodtryk (hypotension) - Væskeophobning - hævede fødder, ankler og hænder (perifert ødem) - Allergiske reaktioner (f.eks. udslæt, kløe, overfølsomhed) - Besvimelse - Rastløshed - Synsnedsættelse (dobbeltsyn) - Vægttab samt nedsat appetit - Åndenød (dyspnø) - Hikke - Lungebetændelse* - Manglende evne til at modstå trangen eller fristelsen til at udføre en handling, der kan være skadelig for dig selv eller andre, og som kan omfatte: 
- Hallucinations (seeing, hearing or feeling things that are not there) - Confusion - Excessive daytime sleepiness and suddenly falling asleep - Weight increase - Hypotension (low blood pressure) - Excess of fluid, usually in the legs (peripheral oedema) - Allergic reactions (e.g. rash, itching, hypersensitivity) - Fainting - Restlessness - Visual impairment - Weight loss including decreased appetite - Dyspnoea (difficulties to breathe) - Hiccups - Pneumonia (infection of the lungs)* - Inability to resist the impulse, drive or temptation to perform an action that could be harmful to you or others, which may include:
Hvid, oval, med skrå kanter, delekærv på begge sider og præget med ”P8” på begge halvdele af den ene side af tabletten. 
White, oval, with bevelled edges, both sides scored, with imprint "P8" on both halves of one side of the tablet.
2 tabletter Oprymea 0,088 mg 3 gange om dagen 
2 tablets Oprymea 0.088 mg three times a day
Hvid, rund, med skrå kanter, delekærv på begge sider og præget med ”P9” på begge halvdele af den ene side af tabletten. 
White, round, with bevelled edges, both sides scored, with imprint "P9" on both halves of one side of the tablet.
Et fase-I studie, hvor pramipexoltabletter blev sammenlignet med pramipexoldepottabletter, viste ækvivalens mellem den samme døgndosis af pramipexol depottabletter givet en gang daglig og pramipexol tabletter givet 3 gange daglig for Cmin, Cmax og AUC. 
In a Phase I trial, where pramipexole immediate release and prolonged-release tablets were assessed in fasted state, the minimum and peak plasma concentration (Cmin, Cmax) and exposure (AUC) of the same daily dose of pramipexole prolonged-release tablets given once daily and pramipexole tablets given three times a day were equivalent.
Man skal være opmærksom på, at hyppigheden af døsighed øges ved doser højere end 1,5 mg (salt)/dag (se pkt. 
However, it should be noted that the incidence of somnolence is increased at doses higher than 1.5 mg (of salt) per day (see section 4.8).
Det skal du vide, før du begynder at tage Oprymea Sådan skal du tage Oprymea Bivirkninger 
What Oprymea is and what it is used for What you need to know before you take Oprymea How to take Oprymea
Oprymea med 3,15 mg depottabletter er hvide til næsten hvide, runde (10 mm i diameter), let hvælvede tabletter, præget med P5 på den ene side og med 315 på den anden side, med skrå kanter og muligvis plettede. 
Oprymea 3.15 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P5 on one side and 315 on the other side, with bevelled edges and possible spots.
I kliniske titreringsforsøg sås en virkning allerede ved en daglig dosis på 1,05 mg base (1,5 mg salt). 
During dose escalation in pivotal studies, efficacy was observed starting at a daily dose of 1.05 mg of base (1.5 mg of salt).
Oprymea 0,7 mg tabletter Pramipexol 
Oprymea 0.7 mg tablets Pramipexole
Hver tablet indeholder 0,088 mg pramipexol (som 0,125 mg pramipexoldihydrochloridmonohydrat). 
Each tablet contains 0.088 mg pramipexole (as 0.125 mg pramipexole dihydrochloride monohydrate).
Sjælden til <1/1.000) 
Rare may affect up to 1 in 1,000 people
Et dobbeltblindet, placebokontrolleret studie med 539 patienter med tidlig Parkinsons sygdom viste, at pramipexol depottabletter havde en bedre virkning (superior) end placebo efter 18 ugers behandling på både det primære (UPDRS del II+III score) og vigtigste sekundære (CGI-I og PGI-I responderhastigheder) endepunkter. 
Superiority of pramipexole prolonged-release tablets over placebo was demonstrated after 18 weeks of treatment on both the primary (UPDRS Parts II+III score) and the key secondary (CGI-I and PGI-I responder rates) efficacy endpoints in a double-blind placebo-controlled trial including a total of 539 patients with early Parkinson's disease.
- 7 depottabletter indeholdende 0,52 mg 
- 7 prolonged-release tablets of 0.52 mg
Oprymea 0,18 mg tabletter Hver tablet indeholder 0,18 mg pramipexol (som 0,25 mg pramipexoldihydrochloridmonohydrat). 
Oprymea 0.18 mg tablets Each tablet contains 0.18 mg pramipexole (as 0.25 mg pramipexole dihydrochloride monohydrate).
Hvide til næsten hvide, runde (10 mm i diameter), let hvælvede tabletter, præget med P13 på den ene side og med 262 på den anden side, med skrå kanter og muligvis plettede. 
White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P13 on one side and 262 on the other side, with bevelled edges and possible spots.
Oprymea 2,62 mg depottabletter Pramipexol 
Oprymea 2.62 mg prolonged-release tablets Pramipexole
Oprymea 0,7 mg tabletter Hver tablet indeholder 0,7 mg pramipexol (som 1 mg pramipexoldihydrochloridmonohydrat). 
Oprymea 0.7 mg tablets Each tablet contains 0.7 mg pramipexole (as 1 mg pramipexole dihydrochloride monohydrate).
- Udtalt træthed om dagen og episoder med pludselig indsættende søvn - Hukommelsestab (amnesi) Øget muskelaktivitet med ufrivillige (hyperkinesi) - Vægtforøgelse - Allergiske reaktioner (f.eks. udslæt, kløe, overfølsomhed) - Besvimelse - Hjertesvigt (hjerteproblemer, der kan forårsage åndenød eller hævede ankler)* - Uhensigtsmæssig udskillelse af antidiuretisk hormon - Rastløshed - Åndenød (dyspnø) - Hikke - Lungebetændelse - Manglende evne til at modstå trangen eller fristelsen til at udføre en handling, der kan være skadelig for dig selv eller andre, og som kan omfatte: - Stærk trang til at spille (sygelig spilletrang) trods alvorlige personlige og familiemæssige konsekvenser. 
- Hyperkinesia (increased movements and inability to keep still) - Weight increase - Allergic reactions (e.g. rash, itching, hypersensitivity) - Fainting - Cardiac failure (heart problems which can cause shortness of breath or ankle swelling)* - Inappropriate antidiuretic hormone secretion* - Restlessness - Dyspnoea (difficulties to breathe) - Hiccups - Pneumonia (infection of the lungs) - Inability to resist the impulse, drive or temptation to perform an action that could be harmful to you or others, which may include:
Mave-tarm-kanalen kvalme forstoppelse, opkastning 
Gastrointestinal disorders nausea constipation vomiting
1 tablet Oprymea 0,088 mg 3 gange om dagen 
1 tablet Oprymea 0.088 mg three times a day
Oprymea 0,18 mg tabletter Pramipexol 
Oprymea 0.18 mg tablets Pramipexole
Du skal afstå fra at køre bil, motorcykel, eller cykel, og lade være med at arbejde med værktøj eller maskiner, hvis du oplever disse bivirkninger. 
If you experience these side effects, you must not drive or operate machinery.
4 tabletter Oprymea 0,088 mg 
4 tablets Oprymea 0.088 mg
Hvide til næsten hvide, runde (10 mm i diameter), let hvælvede tabletter, præget med P5 på den ene side og med 315 på den anden side, med skrå kanter og muligvis plettede. 
White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P5 on one side and 315 on the other side, with bevelled edges and possible spots.
Oprymea depottabletter skal tages en gang daglig. 
Take Oprymea prolonged-release tablets only once a day and each day at about the same time.
2 tabletter Oprymea 0,088 mg 
2 tablets Oprymea 0.088 mg
6 tabletter Oprymea 0,088 mg 
6 tablets Oprymea 0.088 mg
3 tabletter Oprymea 0,18 mg 
3 tablets Oprymea 0.18 mg OR
Tal med din læge. 
Please tell your doctor if this occurs.
Oprymea 0,26 mg Oprymea 0,52 mg Oprymea 1,05 mg depottabletter 
Oprymea 0.26 mg Oprymea 0.52 mg Oprymea 1.05 mg prolonged-release tablets
1 tablet Oprymea 0,18 mg 
1 tablet Oprymea 0.18 mg OR
Hver depottablet indeholder 2,62 mg pramipexol (som 3,75 mg pramipexoldihydrochloridmonohydrat). 
Each prolonged-release tablet contains 2.62 mg pramipexole (as 3.75 mg pramipexole dihydrochloride monohydrate).
Oprymea 1,05 mg: Hver depottablet indeholder 1,05 mg pramipexol (som 1,5 mg pramipexoldihydrochloridmonohydrat). 
Oprymea 1.05 mg: Each prolonged-release tablet contains 1.05 mg pramipexole (as 1.5 mg pramipexole dihydrochloride monohydrate).
Oprymea 0,26 mg Oprymea 0,52 mg Oprymea 1,05 mg depottabletter Pramipexol 
Oprymea 0.26 mg Oprymea 0.52 mg Oprymea 1.05 mg prolonged-release tablets Pramipexole
1 tablet Oprymea 0,18 mg 3 gange om dagen 
1 tablet Oprymea 0.18 mg three times a day OR
Hvis du har Parkinsons sygdom i fremskreden grad og samtidig behandles med levodopa, kan der være risiko for udvikling af ufrivillige bevægelser (dyskinesi), når Oprymea-dosis øges. 
If you have advanced Parkinson's disease and are also taking levodopa, you might develop dyskinesia during the uptitration of Oprymea - Dystonia (inability of keeping your body and neck straight and upright (axial dystonia)).
Oprymea 2,62 mg depottabletter 
Oprymea 2.62 mg prolonged-release tablets
1,05 mg: Hvide til næsten hvide, runde (10 mm i diameter), let hvælvede tabletter, præget med P3 på den ene side, med skrå kanter og muligvis plettede. 
1.05 mg: White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P3 on one side, with bevelled edges and possible spots.
Hvis du har Parkinsons sygdom, bør du ikke stoppe behandlingen med Oprymea pludseligt, da det kan medføre en sygelig tilstand, der udgør en alvorlig helbredsrisiko (malignt neuroleptika syndrom). 
A sudden stop could cause you to develop a medical condition called neuroleptic malignant syndrome which may represent a major health risk.
Hver tablet indeholder 0,35 mg pramipexol (som 0,5 mg pramipexoldihydrochloridmonohydrat). 
Each tablet contains 0.35 mg pramipexole (as 0.5 mg pramipexole dihydrochloride monohydrate).
0,26 mg: Hvide til næsten hvide, runde (10 mm i diameter), let hvælvede tabletter, præget med P1 på den ene side, med skrå kanter og muligvis plettede. 
0.26 mg: White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P1 on one side, with bevelled edges and possible spots.
Hver tablet indeholder 1,1 mg pramipexol (som 1,5 mg pramipexoldihydrochloridmonohydrat). 
Each tablet contains 1.1 mg pramipexole (as 1.5 mg pramipexole dihydrochloride monohydrate).
Oprymea 0,26 mg: Hver depottablet indeholder 0,26 mg pramipexol (som 0,375 mg pramipexoldihydrochloridmonohydrat). 
Oprymea 0.26 mg: Each prolonged-release tablet contains 0.26 mg pramipexole (as 0.375 mg pramipexole dihydrochloride monohydrate).
Oprymea 0,52 mg: Hver depottablet indeholder 0,52 mg pramipexol (som 0,75 mg pramipexoldihydrochloridmonohydrat). 
Oprymea 0.52 mg: Each prolonged-release tablet contains 0.52 mg pramipexole (as 0.75 mg pramipexole dihydrochloride monohydrate).
Hver tablet indeholder 0,7 mg pramipexol (som 1 mg pramipexoldihydrochloridmonohydrat). 
Each tablet contains 0.7 mg pramipexole (as 1 mg pramipexole dihydrochloride monohydrate).
Oprymea 0,35 mg tabletter 20 tabletter: EU/1/08/469/011 30 tabletter: EU/1/08/469/012 60 tabletter: EU/1/08/469/013 90 tabletter: EU/1/08/469/014 100 tabletter: EU/1/08/469/015 
Oprymea 0.35 mg tablets 20 tablets: EU/1/08/469/011 30 tablets: EU/1/08/469/012 60 tablets: EU/1/08/469/013 90 tablets: EU/1/08/469/014 100 tablets: EU/1/08/469/015
Tabletterne kan både tages sammen med mad og alene. 
The tablets may be taken either with or without food and should be taken each day at about the same time.
Oprymea 1,1 mg tabletter 20 tabletter: EU/1/08/469/021 30 tabletter: EU/1/08/469/022 60 tabletter: EU/1/08/469/023 90 tabletter: EU/1/08/469/024 100 tabletter: EU/1/08/469/025 
Oprymea 1.1 mg tablets 20 tablets: EU/1/08/469/021 30 tablets: EU/1/08/469/022 60 tablets: EU/1/08/469/023 90 tablets: EU/1/08/469/024 100 tablets: EU/1/08/469/025
Hver depottablet indeholder 3,15 mg pramipexol (som 4,5 mg pramipexoldihydrochloridmonohydrat). 
Each prolonged-release tablet contains 3.15 mg pramipexole (as 4.5 mg pramipexole dihydrochloride monohydrate).
Hver depottablet indeholder 1,57 mg pramipexol (som 2,25 mg pramipexoldihydrochloridmonohydrat). 
Each prolonged-release tablet contains 1.57 mg pramipexole (as 2.25 mg pramipexole dihydrochloride monohydrate).
Dosis skal øges gradvist hver 5.-7. dag fra en startdosis på 0,264 mg base (0,375 mg salt)/døgn. 
Doses should be increased gradually from a starting-dose of 0.264 mg of base (0.375 mg of salt) per day and then increased every 5 - 7 days.
Den daglige dosis bør være mellem 0,26 mg base (0,375 mg salt) og 3,15 mg base (4,5 mg salt). 
The individual dose of pramipexole should be in the range of 0.26 mg of base (0.375 mg of salt) to a maximum of 3.15 mg of base (4.5 mg of salt) per day.
0,52 mg: Hvide til næsten hvide, runde (10 mm i diameter), let hvælvede tabletter, præget med P2 på den ene side, med skrå kanter og muligvis plettede. 
0.52 mg: White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P2 on one side, with bevelled edges and possible spots.
Oprymea 3,15 mg depottabletter 
Oprymea 3.15 mg prolonged-release tablets
Oprymea 3,15 mg depottabletter Pramipexol 
Oprymea 3.15 mg prolonged-release tablets Pramipexole
Hver tablet indeholder 0,18 mg pramipexol (som 0,25 mg pramipexoldihydrochloridmonohydrat). 
Each tablet contains 0.18 mg pramipexole (as 0.25 mg pramipexole dihydrochloride monohydrate).
Hver depottablet indeholder 2,1 mg pramipexol (som 3 mg pramipexoldihydrochloridmonohydrat). 
Each prolonged-release tablet contains 2.1 mg pramipexole (as 3 mg pramipexole dihydrochloride monohydrate).
EU/1/08/469/011 [20 tabletter] EU/1/08/469/012 [30 tabletter] EU/1/08/469/013 [60 tabletter] EU/1/08/469/014 [90 tabletter] EU/1/08/469/015 [100 tabletter] 
EU/1/08/469/011 [20 tablets] EU/1/08/469/012 [30 tablets] EU/1/08/469/013 [60 tablets] EU/1/08/469/014 [90 tablets] EU/1/08/469/015 [100 tablets]
Oprymea 0,088 mg tabletter er hvide, runde, med skrå kanter og præget med ”P6” på den ene side af tabletten. 
What Oprymea looks like and contents of the pack Oprymea 0.088 mg tablets are white, round, with bevelled edges and imprint "P6" on one side of the tablet.
EU/1/08/469/021 [20 tabletter] EU/1/08/469/022 [30 tabletter] EU/1/08/469/023 [60 tabletter] EU/1/08/469/024 [90 tabletter] EU/1/08/469/025 [100 tabletter] 
EU/1/08/469/021 [20 tablets] EU/1/08/469/022 [30 tablets] EU/1/08/469/023 [60 tablets] EU/1/08/469/024 [90 tablets] EU/1/08/469/025 [100 tablets]
Oprymea 0,18 mg tabletter 20 tabletter: EU/1/08/469/006 30 tabletter: EU/1/08/469/007 60 tabletter: EU/1/08/469/008 90 tabletter: EU/1/08/469/009 100 tabletter: EU/1/08/469/010 
Oprymea 0.18 mg tablets 20 tablets: EU/1/08/469/006 30 tablets: EU/1/08/469/007 60 tablets: EU/1/08/469/008 90 tablets: EU/1/08/469/009 100 tablets: EU/1/08/469/010
Hver depottablet indeholder 1,05 mg pramipexol (som 1,5 mg pramipexoldihydrochloridmonohydrat). 
Each prolonged-release tablet contains 1.05 mg pramipexole (as 1.5 mg pramipexole dihydrochloride monohydrate).
Oprymea med 1,05 mg depottabletter er hvide til næsten hvide, runde (10 mm i diameter), let hvælvede tabletter, præget med P3 på den ene side, med skrå kanter og muligvis plettede. 
Oprymea 1.05 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P3 on one side, with bevelled edges and possible spots.
Oprymea er indiceret til voksne til behandling af tegn og symptomer på idiopatisk Parkinsons sygdom. 
Oprymea is used to treat the symptoms of primary Parkinson's disease in adults.
Oprymea med 1,57 mg depottabletter er hvide til næsten hvide, runde (10 mm i diameter), let hvælvede tabletter, præget med P12 på den ene side, med skrå kanter og muligvis plettede. 
Oprymea 1.57 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P12 on one side, with bevelled edges and possible spots.
Dosis skal øges gradvist hver 5.-7. dag fra en startdosis på 0,26 mg base (0,375 mg salt)/døgn. 
Doses should be increased gradually from a starting dose of 0.26 mg of base (0.375 mg of salt) per day and then increased every 5 - 7 days.
Oprymea 0,7 mg tabletter 20 tabletter: EU/1/08/469/016 30 tabletter: EU/1/08/469/017 60 tabletter: EU/1/08/469/018 90 tabletter: EU/1/08/469/019 100 tabletter: EU/1/08/469/020 
Oprymea 0.7 mg tablets 20 tablets: EU/1/08/469/016 30 tablets: EU/1/08/469/017 60 tablets: EU/1/08/469/018 90 tablets: EU/1/08/469/019 100 tablets: EU/1/08/469/020
Oprymea med 0,52 mg depottabletter er hvide til næsten hvide, runde (10 mm i diameter), let hvælvede tabletter, præget med P2 på den ene side, med skrå kanter og muligvis plettede. 
Oprymea 0.52 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P2 on one side, with bevelled edges and possible spots.
Oprymea 3,15 mg depottabletter 10 depottabletter: EU/1/08/469/050 30 depottabletter: EU/1/08/469/051 90 depottabletter: EU/1/08/469/052 100 depottabletter: EU/1/08/469/053 
Oprymea 3.15 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/050 30 prolonged-release tablets: EU/1/08/469/051 90 prolonged-release tablets: EU/1/08/469/052 100 prolonged-release tablets: EU/1/08/469/053
Oprymea 1,05 mg depottabletter 
Oprymea 1.05 mg prolonged-release tablets
Hos patienter med Parkinsons sygdom og nedsat nyrefunktion bør dosis reduceres, se pkt. 
When prescribing Oprymea in a patient with Parkinson's disease with renal impairment a reduced dose is suggested in line with section 4.2.
Oprymea 1,05 mg depottabletter 10 depottabletter: EU/1/08/469/034 30 depottabletter: EU/1/08/469/035 90 depottabletter: EU/1/08/469/036 100 depottabletter: EU/1/08/469/037 
Oprymea 1.05 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/034 30 prolonged-release tablets: EU/1/08/469/035 90 prolonged-release tablets: EU/1/08/469/036 100 prolonged-release tablets: EU/1/08/469/037
Oprymea med 2,1 mg depottabletter er hvide til næsten hvide, runde (10 mm i diameter), let hvælvede tabletter, præget med P4 på den ene side, med skrå kanter og muligvis plettede. 
Oprymea 2.1 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P4 on one side, with bevelled edges and possible spots.
Skema for dosisøgning af Oprymea 
Ascending - Dose Schedule of Oprymea Week
Oprymea 2,1 mg depottabletter 10 depottabletter: EU/1/08/469/042 30 depottabletter: EU/1/08/469/043 90 depottabletter: EU/1/08/469/044 100 depottabletter: EU/1/08/469/045 
Oprymea 2.1 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/042 30 prolonged-release tablets: EU/1/08/469/043 90 prolonged-release tablets: EU/1/08/469/044 100 prolonged-release tablets: EU/1/08/469/045
EU/1/08/469/001 [20 tabletter] EU/1/08/469/002 [30 tabletter] EU/1/08/469/003 [60 tabletter] EU/1/08/469/004 [90 tabletter] EU/1/08/469/005 [100 tabletter] 
EU/1/08/469/001[20 tablets] EU/1/08/469/002 [30 tablets] EU/1/08/469/003 [60 tablets] EU/1/08/469/004 [90 tablets] EU/1/08/469/005 [100 tablets]
EU/1/08/469/016 [20 tabletter] EU/1/08/469/017 [30 tabletter] EU/1/08/469/018 [60 tabletter] EU/1/08/469/019 [90 tabletter] EU/1/08/469/020 [100 tabletter] 
EU/1/08/469/016 [20 tablets] EU/1/08/469/017 [30 tablets] EU/1/08/469/018 [60 tablets] EU/1/08/469/019 [90 tablets] EU/1/08/469/020 [100 tablets]
Oprymea 2,62 mg depottabletter 10 depottabletter: EU/1/08/469/046 30 depottabletter: EU/1/08/469/047 90 depottabletter: EU/1/08/469/048 100 depottabletter: EU/1/08/469/049 
Oprymea 2.62 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/046 30 prolonged-release tablets: EU/1/08/469/047 90 prolonged-release tablets: EU/1/08/469/048 100 prolonged-release tablets: EU/1/08/469/049
EU/1/08/469/042 [10 depottabletter] EU/1/08/469/043 [30 depottabletter] EU/1/08/469/044 [90 depottabletter] EU/1/08/469/045 [100 depottabletter] 
EU/1/08/469/042 [10 prolonged-release tablets] EU/1/08/469/043 [30 prolonged-release tablets] EU/1/08/469/044 [90 prolonged-release tablets] EU/1/08/469/045 [100 prolonged-release tablets]
Oprymea 1,57 mg depottabletter 10 depottabletter: EU/1/08/469/038 30 depottabletter: EU/1/08/469/039 90 depottabletter: EU/1/08/469/040 100 depottabletter: EU/1/08/469/041 
Oprymea 1.57 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/038 30 prolonged-release tablets: EU/1/08/469/039 90 prolonged-release tablets: EU/1/08/469/040 100 prolonged-release tablets: EU/1/08/469/041
Oprymea 1,57 mg depottabletter 
Oprymea 1.57 mg prolonged-release tablets
Hver depottablet indeholder 0,26 mg pramipexol (som 0,375 mg pramipexoldihydrochloridmonohydrat). 
Each prolonged-release tablet contains 0.26 mg pramipexole (as 0.375 mg pramipexole dihydrochloride monohydrate).
EU/1/08/469/050 [10 depottabletter] EU/1/08/469/051 [30 depottabletter] EU/1/08/469/052 [90 depottabletter] EU/1/08/469/053 [100 depottabletter] 
EU/1/08/469/050 [10 prolonged-release tablets] EU/1/08/469/051 [30 prolonged-release tablets] EU/1/08/469/052 [90 prolonged-release tablets] EU/1/08/469/053 [100 prolonged-release tablets]
EU/1/08/469/006 [20 tabletter] EU/1/08/469/007 [30 tabletter] EU/1/08/469/008 [60 tabletter] EU/1/08/469/009 [90 tabletter] EU/1/08/469/010 [100 tabletter] 
EU/1/08/469/006 [20 tablets] EU/1/08/469/007 [30 tablets] EU/1/08/469/008 [60 tablets] EU/1/08/469/009 [90 tablets] EU/1/08/469/010 [100 tablets]
EU/1/08/469/034 [10 depottabletter] EU/1/08/469/035 [30 depottabletter] EU/1/08/469/036 [90 depottabletter] EU/1/08/469/037 [100 depottabletter] 
EU/1/08/469/034 [10 prolonged-release tablets] EU/1/08/469/035 [30 prolonged-release tablets] EU/1/08/469/036 [90 prolonged-release tablets] EU/1/08/469/037 [100 prolonged-release tablets]
Malta E. J. Busuttil Ltd. 
România KRKA Romania S.R.L., Bucharest
I den første uge er dosis oftest 1 tablet Oprymea á 0,088 mg én gang daglig. 
During the first week, the usual dose is 1 tablet Oprymea 0.088 mg once a day (equivalent to 0.088 mg daily):
EU/1/08/469/046 [10 depottabletter] EU/1/08/469/047 [30 depottabletter] EU/1/08/469/048 [90 depottabletter] EU/1/08/469/049 [100 depottabletter] 
EU/1/08/469/046 [10 prolonged-release tablets] EU/1/08/469/047 [30 prolonged-release tablets] EU/1/08/469/048 [90 prolonged-release tablets] EU/1/08/469/049 [100 prolonged-release tablets]
Oprymea 0,52 mg depottabletter Pramipexol 
Oprymea 0.52 mg prolonged-release tablets Pramipexole
Oprymea 0,52 mg depottabletter 10 depottabletter: EU/1/08/469/030 30 depottabletter: EU/1/08/469/031 90 depottabletter: EU/1/08/469/032 100 depottabletter: EU/1/08/469/033 
Oprymea 0.52 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/030 30 prolonged-release tablets: EU/1/08/469/031 90 prolonged-release tablets: EU/1/08/469/032 100 prolonged-release tablets: EU/1/08/469/033
Oprymea 1,57 mg depottabletter Pramipexol 
Oprymea 1.57 mg prolonged-release tablets Pramipexole
Kan forekomme hos mellem 1 og 10 ud af 100 patienter Ikke almindelig Kan forekomme hos mellem 1 og 10 ud af 1000 patienter Sjælden 
Very common may affect more than 1 in 10 people Common may affect up to 1 in 10 people